These findings not only identified DNA topoisomerase I and mTOR as synergistic therapeutic targets in NF1-deficient tumors but also demonstrated the utility of the zebrafish model for drug discovery in MPNST research. This evidence concerns the gene NF1 and malignant peripheral nerve sheath tumor.